Wendy Boyd
All posts from Wendy Boyd
Wendy Boyd in Historical Parallels,

Progenics Shares Could Double, According To Cantor

Cantor Fitzgerald analyst Mara Goldstein initiated coverage on Progenics Pharmaceuticals, Inc.  with an Overweight rating and $15 price target.

The stock jumped 2.4 percent Wednesday to $6.86; the price target represents a 114 percent upside.

Goldstein believes the company will gain from its busy pipeline in a field where there is little consensus. Progenics works on treatments for “selected oncology markets where treatments and diagnostics intersect.”

“Consensus as to what is needed and how new agents will be adopted varies, and therein lies the opportunity,” Goldstein said in a note.